Skip to main content

Table 1 Baseline clinical characteristics

From: Association between cancer history and second-generation drug-eluting stent thrombosis: insights from the REAL-ST registry

Ā 

ST

(nā€‰=ā€‰253)

Controls

(nā€‰=ā€‰1012)

EST

(nā€‰=ā€‰142)

Controls

(nā€‰=ā€‰568)

LST

(nā€‰=ā€‰53)

Controls

(nā€‰=ā€‰212)

VLST

(nā€‰=ā€‰58)

Controls

(nā€‰=ā€‰232)

Patient characteristics

ā€ƒAge, yrsa

67.9ā€‰Ā±ā€‰10.9

69.7ā€‰Ā±ā€‰10.7

68.0ā€‰Ā±ā€‰10.6

69.5ā€‰Ā±ā€‰10.5

66.4ā€‰Ā±ā€‰12.0

69.5ā€‰Ā±ā€‰11.5

68.9ā€‰Ā±ā€‰10.5

70.1ā€‰Ā±ā€‰10.2

ā€ƒMale sexa

196 (77.5)

768 (75.9)

115 (81.0)

437 (75.2)

40 (75.5)

165 (77.8)

41 (70.7)

176 (75.9)

ā€ƒBMI, kg/m2a

23.6ā€‰Ā±ā€‰3.6

23.8ā€‰Ā±ā€‰3.6

23.9ā€‰Ā±ā€‰3.5

23.8ā€‰Ā±ā€‰3.4

23.7ā€‰Ā±ā€‰4.2

24.0ā€‰Ā±ā€‰3.5

23.0ā€‰Ā±ā€‰3.2

23.7ā€‰Ā±ā€‰3.9

ā€ƒHypertensiona

201 (79.4)

834 (82.4)

112 (78.9)

469 (82.6)

41 (77.4)

176 (83.0)

48 (82.8)

189 (81.5)

ā€ƒDiabetes mellitusa

127 (50.2)

465 (45.9)

67 (47.2)

248 (43.7)

33 (62.3)

107 (50.5)

27 (46.6)

110 (47.4)

ā€ƒDyslipidemiaa

209 (82.6)

846 (83.6)

119 (83.8)

481 (84.7)

44 (83.0)

181 (85.4)

46 (79.3)

184 (79.3)

ā€ƒCurrent smokera

68 (27.0)

205 (20.3)

45 (31.9)

129 (22.8)

9 (17.0)

29 (13.7)

14 (24.1)

47 (20.3)

ā€ƒHemodialysisa

38 (15.0)

73 (7.2)

9 (6.3)

32 (5.6)

21 (39.6)

22 (10.4)

8 (13.8)

19 (8.2)

ā€ƒPrior myocardial infarction

92 (36.4)

289 (28.6)

50 (35.2)

160 (28.2)

20 (37.7)

60 (28.3)

22 (37.9)

69 (29.7)

ā€ƒPrior PCI

122 (48.2)

483 (47.7)

59 (41.5)

260 (45.8)

30 (56.6)

106 (50.5)

33 (56.9)

117 (50.4)

ā€ƒPrior CABG

13 (5.1)

40 (4.0)

6 (4.2)

25 (4.4)

4 (7.5)

7 (3.3)

3 (5.2)

8 (3.4)

ā€ƒPrior stroke

34 (13.4)

89 (8.8)

16 (11.3)

56 (9.9)

11 (20.8)

13 (6.1)

7 (12.1)

20 (8.6)

ā€ƒLVEF, %

50.9ā€‰Ā±ā€‰14.2

56.9ā€‰Ā±ā€‰12.3

48.4ā€‰Ā±ā€‰15.1

57.3ā€‰Ā±ā€‰12.2

52.3ā€‰Ā±ā€‰13.1

55.9ā€‰Ā±ā€‰12.9

55.9ā€‰Ā±ā€‰11.5

57.0ā€‰Ā±ā€‰12.0

Clinical presentation at the index PCIa

ā€ƒSTEMI

69 (27.5)

106 (10.5)

53 (37.9)

65 (11.5)

10 (18.9)

22 (10.4)

6 (10.3)

15 (6.5)

ā€ƒNSTEMI

16 (6.3)

53 (5.2)

11 (7.9)

26 (4.6)

4 (7.5)

17 (8.0)

1 (1.7)

10 (4.3)

ā€ƒUAP

29 (11.5)

124 (12.3)

14 (10.0)

70 (12.4)

9 (17.0)

25 (11.8)

6 (10.3)

29 (12.5)

ā€ƒStable coronary artery disease

137 (54.2)

729 (72.0)

62 (44.3)

403 (71.5)

30 (56.6)

148 (69.8)

45 (77.6)

178 (76.7)

Medication at index PCI

ā€ƒAspirin

249 (98.4)

1006 (99.6)

139 (97.9)

565 (99.5)

52 (98.1)

212 (100.0)

58 (100.0)

229 (99.6)

ā€ƒThienopyridine

244 (96.4)

1003 (99.1)

135 (95.1)

565 (99.5)

52 (98.1)

210 (99.1)

57 (98.3)

228 (98.3)

ā€ƒAnticoagulation

27 (10.7)

104 (10.3)

15 (10.6)

68 (12.0)

7 (13.2)

17 (8.0)

5 (8.6)

19 (8.3)

ā€ƒBeta-blocker

118 (46.6)

437 (43.3)

70 (49.3)

258 (45.4)

26 (49.1)

84 (39.6)

22 (37.9)

95 (41.3)

ā€ƒACEI/ARB

142 (56.1)

621 (61.4)

80 (56.3)

357 (62.9)

30 (56.6)

132 (62.3)

32 (55.2)

132 (56.9)

ā€ƒStatin

173 (68.4)

769 (76.1)

94 (66.2)

447 (78.7)

38 (71.7)

158 (74.5)

41 (70.7)

164 (71.3)

ā€ƒOral hypoglycemia agent

73 (28.9)

304 (30.1)

38 (26.8)

162 (28.5)

19 (35.8)

70 (33.0)

16 (27.6)

72 (31.3)

ā€ƒInsulin

32 (12.6)

93 (9.2)

17 (12.0)

46 (8.1)

9 (17.0)

27 (12.7)

6 (10.3)

20 (8.7)

Lesion and procedural characteristics

ā€ƒLMCA

22 (8.7)

47 (4.6)

16 (11.3)

23 (4.0)

3 (5.7)

13 (6.1)

3 (5.2)

11 (4.7)

ā€ƒProximal LAD

82 (32.4)

225 (22.2)

53 (37.3)

138 (24.3)

11 (20.8)

51 (24.1)

18 (31.0)

36 (15.5)

ā€ƒIn-stent restenosis

37 (14.6)

97 (9.6)

13 (9.2)

45 (7.9)

10 (18.9)

25 (11.8)

14 (24.1)

27 (11.6)

ā€ƒBifurcation lesion

115 (45.5)

369 (36.5)

71 (50.0)

219 (38.6)

16 (30.2)

68 (32.1)

28 (48.3)

82 (35.3)

ā€ƒSevere calcification

66 (26.1)

141 (13.9)

31 (21.8)

78 (13.7)

28 (52.8)

31 (14.6)

7 (12.1)

32 (13.8)

ā€ƒTortuosity

59 (23.3)

189 (18.7)

25 (17.6)

94 (16.5)

13 (24.5)

39 (18.4)

21 (36.2)

56 (24.1)

ā€ƒChronic total occlusion

14 (5.5)

92 (9.1)

6 (4.2)

47 (8.3)

2 (3.8)

21 (9.9)

6 (10.3)

24 (10.3)

ā€ƒTotal stent length, mm

33.5ā€‰Ā±ā€‰19.5

30.5ā€‰Ā±ā€‰18.2

34.0ā€‰Ā±ā€‰18.7

29.6ā€‰Ā±ā€‰16.9

31.2ā€‰Ā±ā€‰18.0

31.3ā€‰Ā±ā€‰19.3

34.4ā€‰Ā±ā€‰22.5

32.0ā€‰Ā±ā€‰20.0

ā€ƒStent overlap

91 (36.0)

250 (24.7)

51 (35.9)

132 (23.2)

17 (32.1)

55 (25.9)

23 (39.7)

63 (27.2)

ā€ƒIVUS use

185 (73.1)

668 (66.0)

102 (71.8)

376 (66.2)

44 (83.0)

140 (66.0)

39 (67.2)

152 (65.5)

ā€ƒOCT use

16 (6.3)

127 (12.5)

7 (4.9)

87 (15.3)

3 (5.7)

20 (9.4)

6 (10.3)

20 (8.6)

ā€ƒStent edge dissection

2 (0.8)

6 (0.6)

2 (1.4)

4 (0.7)

0 (0.0)

0 (0.0)

0 (0.0)

2 (0.9)

ā€ƒCancer historya

31 (12.3)

86 (8.5)

14 (9.9)

55 (9.7)

7 (13.2)

12 (5.7)

10 (17.2)

19 (8.2)

ā€ƒā€ƒCurrently diagnosed cancera

9 (3.6)

14 (1.4)

3 (2.1)

10 (1.8)

1 (1.9)

1 (0.5)

5 (8.6)

3 (1.3)

ā€ƒā€ƒPreviously diagnosed cancera

22 (8.7)

72 (7.1)

11 (7.7)

45 (7.9)

6 (11.3)

11 (5.2)

5 (8.6)

16 (6.9)

ā€ƒā€ƒCurrently treated cancer

8 (3.2)

13 (1.3)

2 (1.4)

11 (1.9)

2 (3.8)

1 (0.5)

4 (6.9)

1 (0.4)

ā€ƒā€ƒPreviously treated cancer

12 (4.7)

36 (3.6)

6 (4.2)

22 (3.9)

3 (5.7)

3 (1.4)

3 (5.2)

11 (4.7)

  1. Values are expressed as the meanā€‰Ā±ā€‰standard deviation or n (%)
  2. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, CABG coronary artery bypass graft, EST early stent thrombosis, IVUS intravascular ultrasound, LAD left anterior descending, LMCA left main coronary artery, LST late stent thrombosis, LVEF left ventricular ejection fraction, NSTEMI non-ST elevation myocardial infarction, OCT optical coherence tomography, PCI percutaneous coronary intervention, ST stent thrombosis, STEMI ST elevation myocardial infarction, UAP unstable angina pectoris, VLST very late stent thrombosis
  3. aVariables used for multivariable logistic analyses evaluating the predictors of each type of ST